In 2023, the U.S. Food and Drug Administration (FDA) approved one respiratory syncytial virus (RSV) vaccine and an updated monoclonal antibody therapy to prevent respiratory disease in very young children.
Given these were new options, health officials did not know which product pregnant women would prefer during the 2023-2024 RSV season.
Read More
